Search clinical trials for: Gilotrif

Total 44 results

Boehringer Ingelheim

Completed

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Lung Neoplasms

Hong Kong, Korea, Republic of, Spain, Singapore, China, United Kingdom, Taiwan, Canada, Australia, Germany, Ireland, Sweden, France, Norway
Boehringer Ingelheim

Completed

Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (LUX-Lung-IO)

Carcinoma, Non-Small-Cell Lung

Spain, Korea, Republic of, Turkey, France, United States
Yale University
Boehringer Ingelheim; National Comprehensive Cancer Network

Recruiting

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Squamous Cell Cancers of the Head and Neck

United States
Boehringer Ingelheim

Completed

GIOTRIF rPMS in Korean Patients With NSCLC

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Merus N.V.

Recruiting

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Metastatic Castration-resistant Prostate Cancer | NSCLC Harboring NRG1 Fusion

United States
Seoul St. Mary's Hospital
Boehringer Ingelheim

Active, not recruiting

Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

NSCLC

Korea, Republic of
Samsung Medical Center

Completed

Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

Non-small Cell Lung Cancer
National Cancer Centre, Singapore

Terminated

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

Non-small Cell Lung Cancer | Leptomeningeal Disease | Central Nervous System Metastases

Singapore
Santosh Kesari
Boehringer Ingelheim

Completed

Safety Study of Afatinib for Brain Cancer

Brain Cancer

United States
University of Alabama at Birmingham

Terminated

Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma

Penile Squamous Cell Carcinoma (PSCC)

United States
Boehringer Ingelheim

No longer available

Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)

Solid Tumors
National University Hospital, Singapore

Not yet recruiting

Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

NSCLC

Singapore
SCRI Development Innovations, LLC
Bayer; Boehringer Ingelheim; Exelixis; Foundation Medicine

Completed

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Non-small Cell Lung Carcinoma | Urothelial Carcinoma | Gastrointestinal Carcinoma, Non-colon | Upper Aerodigestive Tract Carcinoma

United States
Massachusetts General Hospital
Boehringer Ingelheim; Incyte Corporation

Not yet recruiting

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Cholangiocarcinoma | Advanced Solid Tumor | Metastatic Solid Tumor | Unresectable Solid Tumor

United States
Chonnam National University Hospital

Completed

Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA (LiquidLung-A)

Lung Neoplasms | EGFR Gene Mutation

Korea, Republic of
National University Hospital, Singapore
Boehringer Ingelheim

Recruiting

Observational Study of Afatinib 30 mg Daily

Non-Small Cell Lung Cancer | Epidermal Growth Factor Receptor Mutation

Singapore
Leiden University Medical Center
Boehringer Ingelheim; Chordoma Foundation

Active, not recruiting

Afatinib in Locally Advanced and Metastatic Chordoma

Chordoma

United Kingdom, Netherlands, Italy
The University of Hong Kong

Completed

Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC

Lung Cancer

Hong Kong
Boehringer Ingelheim

Completed

The START Study Observes Afatinib as First-line Treatment and Sequential Therapy in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Nonsmall Cell Lung Cancer

Non-squamous, Non-Small Cell Lung Cancer

China
University College, London
Boehringer Ingelheim

Completed

Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity (DARWIN1)

Non-small Cell Lung Cancer

United Kingdom
University Health Network, Toronto
Boehringer Ingelheim

Completed

A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

Solid Tumors

Canada
ETOP IBCSG Partners Foundation

Completed

Afatinib in NSCLC With HER2 Mutation (NICHE)

NSCLC

Switzerland, Germany, Spain, Netherlands
Boehringer Ingelheim

Completed

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Non-squamous, Non-Small Cell Lung Cancer

Japan
University of Chicago
National Cancer Institute (NCI)

Recruiting

Afatinib in Advanced Refractory Urothelial Cancer

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Ureter Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Stage III Urethral Cancer | Stage IV Urethral Cancer

United States
Shanghai Chest Hospital

Unknown

To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation

Lung Squamous Cell Carcinoma

China
Shanghai Chest Hospital

Not yet recruiting

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

NRG1-fused Non-small Cell Lung Cancer

China
National Taiwan University Hospital

Recruiting

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

NSCLC Stage IV

Taiwan
Dana-Farber Cancer Institute
National Comprehensive Cancer Network

Completed

Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
BioGene Pharmaceutical Ltd.

Withdrawn

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)

Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis Externa

Switzerland
University of California, Davis
National Cancer Institute (NCI)

Completed

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Cambridge University Hospitals NHS Foundation Trust
Boehringer Ingelheim; Cancer Research UK; University of Cambridge; The Brain Tumour...

Terminated

Cambridge Brain Mets Trial 1 (CamBMT1)

Breast Cancer | Advanced Breast Cancer | Lung Cancer | Brain Cancer | Advanced Lung Cancer

United Kingdom
National Taiwan University Hospital

Completed

Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study) (ALPHA)

Head and Neck Neoplasms

Taiwan
AIO-Studien-gGmbH
Boehringer Ingelheim

Terminated

Maintaining ERBB Blockade in EGFR-mutated Lung Cancer (MARBLE)

Non-small-cell Lung Cancer With Somatic EGFR Mutations

Germany
Jeeyun Lee

Not yet recruiting

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

Stomach Neoplasm
Guangdong Association of Clinical Trials

Recruiting

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study (BELLA)

NSCLC

China
Shanghai Jiao Tong University School of Medicine
Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital

Recruiting

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Gallbladder Carcinoma

China
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
University of Washington

Completed

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

Advanced Malignant Solid Neoplasm | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Recurrent Malignant Solid Neoplasm | Stage IVA Pancreatic Cancer | Stage IVB Pancreatic Cancer | Bile Duct Carcinoma

United States
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Recruiting

Pilot Trial for Treatment of Recurrent Glioblastoma

Glioblastoma | Recurrent Glioblastoma | Recurrent Disease

Canada
PD Dr. med. Volker Heinemann
University of Cologne; Technical University of Munich

Unknown

Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer (AFFECT)

Metastatic Pancreatic Cancer

Germany
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Guangdong Association of Clinical Trials
Chinese Thoracic Oncology Group

Recruiting

Phase II Umbrella Study Directed by Next Generation Sequencing (TRUMP)

Carcinoma, Non-Small-Cell Lung

China
The Netherlands Cancer Institute
Bristol-Myers Squibb; Eli Lilly and Company; Bayer; GlaxoSmithKline; Merck Sharp... and other collaborators

Recruiting

The Drug Rediscovery Protocol (DRUP Trial) (DRUP)

Cancer | Neoplasm | Tumors | Neoplasia

Netherlands
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam

Search clinical trials for: Gilotrif

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations